Cambridge-based clinical-stage biopharmaceutical company Synlogic, Inc. has announced its pioneering work in developing synthetic biotics to treat metabolic and immunological diseases in the United States. Synlogic's pipeline comprises a range of orally administered, non-systemically absorbed drug candidates, including SYNB1618, a candidate to treat phenylketonuria; SYNB1934, in Phase III clinical trials, to treat phenylketonuria; SYNB1353, in Phase II clinical trials to treat homocystinuria; and SYNB8802, also in Phase II clinical trials, for the treatment of enteric hyperoxaluria. Most recently, Synlogic has also developed SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. Synlogic has recently entered into a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease, and with Ginkgo Bioworks, Inc. for research into the development of new medicines.
Synlogic's ticker is SYBX
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Synlogic
It is synlogictx.com
Synlogic is in the Healthcare sector
Synlogic is in the Biotechnology industry
The following five companies are Synlogic's industry peers: